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ABSTRACT 
 
 
 Fracture non-unions occur when the biological process of fracture healing 
fails to complete.  The events that occur in the fracture healing process of mice 
are similar to the events that occur in humans.  Inorganic phosphate is essential 
for maintaining healthy bones.  In this study mice are placed on a phosphate 
deficient diet two days prior to fracture of the right femur.  The mice were then 
maintained for 5, 10, 15, and 20 days of restricted diet and compared to control 
animals.  The progression of fracture healing was assessed by plain film x-ray 
radiography and biological healing was assessed by analyzing mRNA expression 
for marker genes for cartilage and bone formation.  Initial removal of the 
phosphate from the diet will delay the completion of the normal fracture healing 
process and produce delayed union with progressively longer periods of delay 
commensurate with the period of dietary restriction.  When phosphate is re-
introduced to the diet, the fracture healing process is reinitiated; however, 
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progressively longer periods of times are needed to achieve union based on the 
period of initial phosphate restriction. 
vi 
 
TABLE OF CONTENTS 
 
Title           i 
Reader’s Approval Page        ii    
Acknowledgements         iii 
Abstract          iv 
Table of Contents         vi 
List of Tables         viii 
List of Figures         ix 
List of Abbreviations        x 
Introduction          1 
 Process of Normal Fracture Healing & Bone Formation  1 
Non-Unions         10 
Experimental Goals        15 
Methods          17 
 Animals         17 
 Phosphate Deficient Diet       17 
 Surgical Procedure        18 
 Post-operative Treatment       20 
 Femora Harvesting        20 
 RNA Extraction        21 
 cDNA Generation & qPCR Reaction     22 
vii 
 
 Statistical Methods        23 
Results          25 
 Radiographic Evaluation       25 
 qPCR Analysis        34 
Discussion           42 
 Effects on Gene Expression      42 
 Future Directions        43 
References          45 
Vita           50 
viii 
 
LIST OF TABLES 
 
Table Title Page  
1 
2 
3 
4 
Stages of Fracture Healing with Signaling Molecules 
Etiology of Non-unions 
Types of Non-unions 
Study Design 
9 
11 
13 
16 
5 Number of Bridging Calluses Two Weeks after Injury 33 
   
   
   
   
   
   
   
   
   
   
 
ix 
 
LIST OF FIGURES 
 
Figure  Title Page  
1 Locations involved in Fracture Healing 2 
2 Normal Timeline associated with Fracture Healing 5 
3 
4 
Histology of Fracture Healing  
Visual Representation of Non-unions 
6 
14 
5 Day 3 Radiographs 25 
6 Day 5 Radiographs 26 
7 Day 7 Radiographs 26 
8 Day 10 Radiographs 27 
9 Day 14 Radiographs 28 
10 
11 
 
12 
Day 18 Radiographs 
Day 21 Radiographs 
Day 28 Radiographs 
29 
30 
31 
13 Day 35 Radiographs 32 
14 qPCR Analysis: Chondrogenesis (I)   36 
15 
16 
17 
qPCR Analysis: Chondrogenesis (II) 
qPCR Analysis: Osteogenesis (I) 
qPCR Analysis: Osteogenesis (II) 
37 
40 
41 
 
x 
 
LIST OF ABBREVIATIONS 
 
AAALAC American Association for the Accreditation of Laboratory Animal  
Care 
B6  C57BL/6J strain of mice 
cDNA  complementary deoxyribonucleic acid 
DNA  deoxyribonucleic acid 
IACUC Institutional Animal Care and Use Committee  
LASC  Laboratory Animal Sciences Center 
µCT  micro-computed tomography 
µg  microgram 
µL  microliter 
NSAIDs non-steroidal anti-inflammatory drugs  
Pi  inorganic phosphate 
PCR  polymerase chain reaction 
qPCR  quantitative real time polymerase chain reaction 
RNase ribonuclease 
RNA  ribonucleic acid 
rRNA  ribosomal ribonucleic acid 
TNF-α  tumor necrosis factor – alpha 
USDA  United States Department of Agriculture   
VEGF  vascular endothelial growth factor 
xi 
 
5DR  5 day phosphate restrictive 
10DR  10 day phosphate restrictive 
15DR  15 day phosphate restrictive 
20DR  20 day phosphate restrictive 
 
 
1 
 
INTRODUCTION 
 
 The number of fractures treated since the late 1990s has remained fairly 
constant, with approximately 13 million fractures treated in 2004 (United States 
Bone and Joint Initiative, 2011).  Although the majority of fractures heal without 
any associated problems, approximately 5 to 10 % of fractures in the United 
States exhibit delayed or impaired healing (Einhorn, 1995).  Fractures that fail to 
heal within six to eight months are classified as non-unions.  The goal of this 
study was to generate a murine non-union model to aid in the development of 
non-surgical, therapeutic approaches to promote the normal healing of these 
fractures.  Specifically, this project was conducted to evaluate the role that 
phosphate plays in the progression of the normal fracture healing process, with 
the hypothesis that a fracture that occurs during the restriction of phosphate in 
the murine diet for a specific length of time will lead to a femoral non-union.  
 
Process of Normal Fracture Healing & Bone Formation 
The process of fracture healing involves re-initiating specific aspects of 
molecular and cellular events that occur during embryonic endochondral bone 
formation (Gerstenfeld, Cullinane, Barnes, Graves, & Einhorn, 2003).  The four 
locations in Figure 1 are contiguous with the fracture site and interact with each 
other to start the process of fracture healing.  These locations are the external 
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soft tissue, the periosteum, the cortex or cortical bone, and the bone marrow 
space.    
 
Figure 1.  Locations involved in Fracture Healing.  Figure taken from Einhorn, 1995. 
 
The initial response to a fracture involves the bone marrow space, where a 
hematoma forms from the disruption of blood vessels in the surrounding area.  
This is followed by a removal of blood vessels in the area of the fibrin clot, as well 
as a rearrangement of cellular densities in the bone marrow space with high 
density observed adjacent to the fracture site, and a loss of normally observed 
bone marrow organization (Brighton and Hunt, 1991).  From a histological 
perspective, the healing of a fracture can be classified as a primary fracture 
healing or a secondary fracture healing.  Primary fracture healing occurs when 
the two sides of the cortex are in direct contact with each other.  This can be  
achieved through rigid fixation of the bone at the fracture, allowing osteoclasts to 
resorb bone and reform the Haversian canals, allowing blood vessels, that 
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contain endothelial and perivascular mesenchymal cells that develop into 
osteoprogenitor cells, to enter the bone  (Lee, Choi, Behrens, DeFouw, & 
Einhorn, 1998).  Secondary fracture healing is more likely for most forms of 
fixation such as casting and the use of intermedullary rods in which there is 
enhanced motion at the fixation site (Lee et al., 1998).  In secondary fracture 
healing, the external soft tissue and the periosteum, which contains 
osteoprogenitor cells and uncommitted mesenchymal cells, re-initiate the 
processes of embryonic intramembranous ossification and endochondral bone 
formation (Einhorn, 1998).  The two processes work in concert to promote union 
(Gerstenfeld et al., 2003).   
In intramembranous ossification, bone is generated without the formation 
of a cartilage framework.  This process develops distal to the fracture site, and 
biomechanical function is initially restored when the bridging of bone occurs over 
the fracture site (Gerstenfeld et al., 2006).  The process of intramembranous 
ossification occurs within a few days of fracture.  Endochondral bone formation is 
the other process that occurs in secondary fracture healing.  The length of time 
required to complete this process varies depending on the location of the fracture 
site and the relative stability of the bone.  The process can last up to several 
months.  In mice, this process usually takes approximately two weeks; however, 
in larger animals the process can last up to three months.  The distinguishing 
feature of endochondral bone formation is the development of a cartilage 
scaffolding called a callus.  As healing progresses, the cartilage of the callus 
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becomes calcified and is replaced by woven bone (Ross & Pawlina, 2010).  Once 
the woven bone, which is also referred to as immature bone, is created, the next 
process that occurs is the formation of lamellar, or mature bone, by remodeling 
the woven bone (Gerstenfeld et al., 2003). 
The timeline associated with fracture healing occurs in five separate 
phases as illustrated in Figure 2.  Upon fracture, the initial response is a 
hemorrhage at the fracture site, followed by the inflammatory response.  
Angiogenesis occurs and osteoprogenitor cells will differentiate into osteoblasts 
where there is a blood supply.  Mesenchymal cells will differentiate into 
chondrocytes in areas lacking an immediate blood supply.  The chondrocytes will 
generate the callus to act as scaffolding around the fracture site and to stabilize 
the two segments of bone.  Once this initial stability is established blood vessels 
will be recruited into the callus, and the osteoblasts will begin to create woven 
bone.  Once there is a sufficient amount of woven bone, endochondral bone 
formation occurs, and the chondrocytes of the callus will begin to calcify.  The 
final step involves the resorption of the mineralized cartilage and excess bone 
and the transition of woven bone to lamellar bone.  Figure 3 provides a histologic 
overview of the various stages observed in fracture healing. 
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Figure 2.  Normal Timeline associated with Fracture Healing.  The major steps involved in fracture 
healing are listed in the right column with the associated timeframe in the left column.  Figure taken from 
Vaughn, 2008. 
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Figure 3.  Histology of Fracture Healing.  Specimens utilized for histologic staining came from the 
sagittal plane of a mouse tibia that was fractured in the transverse plane.  Magnification is 200X.  Safranin 
O and fast green were the stains used.  A. 24 hours post fracture.  B. Preliminary response of the 
periosteum with endochondral formation 7 days after fracture.  Arrows point to vascular ingrowth to 
fracture site.  C.  Primary bone formation 14 days following fracture.  Arrows indicate new vascular 
ingrowth.  Inset shows osteoclast resorbing calcified cartilage.  D. 21 days after fracture.  Inset depicts 
osteoclast resorbing primary bone.  Figure taken from Gerstenfeld et al., 2006.  
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 Stem cells and the molecular signals that determine the fate of stem cells 
have an essential role in the progression of the healing process that occurs after 
a fracture.  The bone marrow space, the periosteum, and the soft tissue adjacent 
to the bone all contain stem cells that are required for fracture healing.  
Osteoprogenitor cells in the periosteum develop into osteoblasts during 
intramembranous bone formation (Gerstenfeld et al., 2003).  Osteoblasts first 
form osteoid, the un-mineralized portion of bone, and then act in the process of 
mineralizing the bone.  They are responsible for generating the initial bone that 
develops after fracture, the woven bone.  The cells of the periosteum also play 
an important role in releasing signaling molecules. Bone morphogenetic proteins 
(BMP), which are the most potent osteoinductive proteins, are released from 
cells in the periosteum and act as signaling molecules, recruiting other stem cells 
to the fracture site (Bostrom et al., 1995).  Implanting BMPs or mesenchymal 
stem cells into the fracture site will recapitulate the endochondral ossification 
sequence in its entirety, where chondrogenesis precedes bone formation 
(Gerstenfeld et al., 2002).  One of the potential causes of fracture non-union may 
be attributed to a failure of the normal progression of the chondrogenic phases 
(Ekholm et al., 1995). 
 An essential element of fracture healing is the development of new 
capillaries from pre-existing blood vessels to supply blood to the fracture site (Lu, 
Marcucio, & Miclau, 2006).  This process of angiogenesis is regulated by 
vascular endothelial growth factors (VEGF) and angiopoietins.   Many studies 
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have been conducted to evaluate the role of angiogenesis and VEGF in fracture 
healing (Glowacki, 1998; Einhorn and Lee, 2001; Gerstenfeld et al., 2003, Ai-Aql 
et al., 2008).  A study utilizing an antibody that blocks the VEGF receptor has 
been shown to decrease angiogenesis and ultimately inhibit healing, due in part 
to an autocrine role that VEGF has on osteoblasts (Street et al., 2002).  
Conversely, the same study showed that delivery of exogenous VEGF during 
fracture repair increased blood vessel formation and ultimately increased bone 
formation (Street et al., 2002). 
 Another important signaling molecule that is released during the fracture 
healing process is tumor necrosis factor-alpha (TNF-α).  In endochondral bone 
formation, the chondrocytes of the callus are responsible for releasing TNF-α 
which brings mesenchymal stem cells to the fracture site and causes apoptosis 
of hypertrophic chondrocytes (AI-Aql, Alagl, Graves, Gerstenfeld, & Einhorn, 
2008).  Table 1 includes the major signaling molecules that are released during 
the various stages of fracture healing. 
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Table 1.  Stages of Fracture Healing with Signaling Molecules.  The table lists the stage, biological 
process, and signaling molecules released (along with their associated function), during the fracture healing 
process.  Interleukin 1 (IL-1) and interleukin 6 (IL-6) are cytokines that act as signaling molecules during 
the inflammatory response.   Receptor activator of nuclear factor kappa-B ligand (RANKL), a surface 
bound protein on osteoblasts, and macrophage colony-stimulating factor (MCSF) expression increases 
during woven bone formation.  Table taken from Ai-Aql et al., 2008. 
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Non-Unions 
 Current literature on non-unions provides differing views on the timeframe 
associated with the diagnosis of a non-union; however, the consensus is that a 
physiological state of non-union occurs when the normal healing progression 
ceases and complete bone healing will not occur without intervention  (Browner, 
2009).  The etiology of non-unions reveals that they are primarily the result of 
excessive instability of the bone, inadequate supply of blood, and/or poor bone-
to-bone contact.  Even in the presence of a sufficient blood supply to the fracture 
site, excessive relative motion between the two ends of the bone can lead to an 
increased callus size, which widens the fracture line and can lead to a failure of 
cartilage mineralization, resulting in non-union (Browner, 2009).  Studies have 
shown that soft tissue injury resulting in inadequate vascularization of the fracture 
site can increase the likelihood of non-union  (Harley, Beaupre, Jones, Dulai, & 
Weber, 2002; Chatziyiannakis, Verettas, Raptis, & Charpantitis, 1997).  The 
distance between the two ends of the fracture can reach a point called a critical 
defect where non-union will occur without intervention, stressing the necessity of 
sufficient proximity between the fractured bone ends (Mahendra & Maclean, 
2007).  Other factors that contribute to non-union include infection, nicotine, and 
non-steroidal anti-inflammatory drugs (NSAIDs).  Infection at the site of fracture 
has been shown to decrease the likelihood of union (Harley et al., 2002).  
Cigarette smoking has a detrimental effect on fracture healing, with nicotine 
inhibiting vascular ingrowth and initial revascularization of the fracture site 
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(Daftari et al., 1994).  Osteoblasts are also adversely affected with a decrease in 
normal function associated with the use of nicotine products (De Vernejoul et al., 
1983).   Multiple studies have indicated that there is an association between the 
use of NSAIDs and delayed union or non-union, although the mechanism of 
action remains unknown (Giannoudis et al., 2000; Khan, 1997; Butcher & Marsh, 
1996).  Table 2 provides a list of the known and suspected causes of non-unions. 
 
Table 2.  Etiology of Non-unions.  The following is a list of known and suspected conditions that can 
contribute to the development of non-union following fracture.  Table modified from Browner, 2009. 
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 Non-unions can be classified as one of five types listed in Table 3.  A 
visual representation is presented in Figure 4.  The types of non-unions are 
hypertrophic, oligotrophic, atrophic, infected, and synovial pseudoarthrosis.  
Hypertrophic non-unions are characterized by a sufficient blood supply with 
formation of an abundant callus; however these non-unions lack the mechanical 
stability necessary for the mineralization of fibrocartilage (Müller, Schenk, & 
Willenegger, 1968; Rhinelander, 1968).  Oligotrophic non-unions are classified 
based on a sufficient blood supply, little callus formation, and insufficient bone-to-
bone contact at the fracture site.  Atrophic non-unions have poor blood supply 
and are treated by an autogenous cancellous graft laid onto a decorticated area 
at the fracture site along with external or internal fixation (Browner, 2009).  
Infected non-unions are considered the most difficult non-unions to treat, and the 
problems associated with non-union are exacerbated by symptoms of the 
infection including incapacitating pain, soft tissue problems, and motor and 
sensory dysfunction among other factors (Browner, 2009).  Effective treatment 
strategies depend on the nature of the infection (active non-draining, quiescent 
non-draining, and draining) (Roberts, 1998).  Synovial pseudoarthroses are 
characterized by a fixed pseudocapsule similar to the synovium and fluid that is 
bound by sealed medullary canals.  Studies have shown that a gradual increase 
in compression of the pseudoarthrosis results in local inflammation and necrosis 
which stimulates the healing process (Schwartsman, Choi, & Schwartsman, 
1990; Ilizarov, Kaplunov, Degtiarev, & Lediaev, 1972). 
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Table 3.  Types of Non-unions.   The types of non-unions and their associated characteristics are provided.  
Figure taken from Browner, 2009.      
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Figure 4.  Visual Representation of Non-unions.  The figure shows graphical representation of the 
various subtypes of non-unions.  Figure taken from Browner, 2009.                                                             
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Experimental Goals 
 This study was conducted under the hypothesis that prolonged phosphate 
deficiency in mice during fracture healing will inhibit the endochondral bone 
formation progression and ultimately lead to non-union.  Previous studies 
conducted utilizing acute dietary phosphate deficiency in mice have been shown 
to impair fracture healing (Wigner et al., 2010).  Normal phosphate levels are 
necessary for maturation of the growth plate as well as regulation of apoptosis of 
hypertrophic chondrocytes by initiating the caspase-9-mediated pathway 
(Sabbagh, Carpenter, & Demay, 2005).  To test the hypothesis, C57BL/6J (B6) 
strain of mice were placed on a phosphate restricted diet two days prior to 
fracture.  The mice remained on the phosphate restricted diet during fracture 
healing for either 5, 10, 15, or 20 days, and were subsequently returned to a 
normal diet containing standard dietary phosphate levels.  The study tested 
whether there is a timeframe of phosphate deficiency that will prevent the normal 
fracture repair process from proceeding even after phosphate is returned to the 
diet.  Three mice were utilized for each time point of evaluation under varying 
timeframes of phosphate restriction as seen in Table 4. 
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Table 4.  Study Design.  A total of five groups (including control) were utilized for this pilot study.  Three 
mice were used for each time point of evaluation.  The time points ranged from 3 to 35 days and indicate 
the number of days after fracture.  The phosphate (Pi) restriction groups were placed on the restricted diet 
two days prior to fracture of the right femur.  Following completion of the timeframe of phosphate 
restriction (5, 10, 15, or 20 days), the mice were returned to a normal diet that included phosphate. 
 
 3 
Day 
5 
Day 
7 
Day 
10 
Day 
14 
Day 
18 
Day 
21 
Day 
28 
Day 
35 
Day 
 
Control 
 
3 
 
3 
 
3 
 
3 
 
3 
 
3 
 
3 
 
3 
 
3 
5 Day Pi 
Restriction 
(5DR) 
 
3 
 
3 
 
3 
 
3 
 
3 
 
3 
 
3 
 
3 
 
3 
10 Day Pi 
Restriction 
(10DR) 
   
3 
 
3 
 
3 
 
3 
 
3 
 
3 
 
3 
15 Day Pi 
Restriction 
(15 DR) 
     
3 
 
3 
 
3 
 
3 
 
3 
20 Day Pi 
Restriction 
(20DR) 
      
3 
 
3 
 
3 
 
3 
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METHODS 
 
Animals 
A total of 102 male mice were used for the study.  The strain of mice used 
was C57BL/6J (B6), which exhibits a faster progression of endochondral bone 
formation compared to the other commonly used A/J and C3H/HeJ strains of 
laboratory mice (Jepsen et al., 2008).  All animals were purchased from Jackson 
Laboratories, Bar Harbor, Maine, and were given three days to acclimate to their 
environment at the Boston University School of Medicine Laboratory Animal 
Sciences Center (LASC) before being placed on the phosphate restrictive diet.  
At the time of placement on the special diet, all of the mice were approximately 
10 to 12 weeks old.  Male mice were used in the study because of sexual 
dimorphism in skeletal structure and the effects that estrogen has on bone 
metabolism, both of which have the potential to alter and confound experimental 
measures (Seeman, 2001; Smith et al., 2008).  All of the animals were weighed 
at the beginning of the study.  The weights of the mice ranged from 23 to 28 
grams with an average weight of 25 grams.  Any animal showing weight loss of 
more than 20% during the study was removed from the study.  Two of the 
animals died during the study as a result of fight wounds from other mice housed 
in the same cage. 
 
Phosphate Deficient Diet 
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Teklad Custom Research Diet, product TD.03486, was obtained by 
request from Harlan Laboratories (Madison, WI).  The diet is provided as a 
standard formulation but devoid of phosphate.  Animals were placed on the diet 
two days prior to fracture of the right femur.  Animals in their respective 
enrollment groups were subsequently returned to the normal diet after 5, 10, 15, 
or 20 days on the phosphate restrictive diet. 
 
Surgical Procedure 
All of the surgical procedures conducted on the mice took place at the 
LASC following a protocol that was reviewed and subsequently approved by the 
Institutional Animal Care and Use Committee (IACUC).  The LASC facility is 
accredited by the American Association for the Accreditation of Laboratory 
Animal Care (AAALAC) and licensed by the United States Department of 
Agriculture (USDA).  The facility is utilized by members of the Boston University 
School of Medicine who are conducting research on laboratory animals under 
approved federal guidelines. 
Prior to any procedures, the experimental animals were anesthetized by 
inhalation of an isoflourane and oxygen mix.  The isoflourane was 5 % of the 
inhalant for induction and maintained at 1 - 3 % during the procedure. The 
animals were kept under anesthetic by a nose cone which covered the animal’s 
entire head throughout the duration of the surgical procedure.  The right knee 
was shaved with an electric shaver.  Hair was brushed away from the field with 
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dampened gauze.  Before any incision was made, a dose of 0.5 mg/kg of 
Buprenex® (Reckitt Benckiser Pharmaceuticals Inc., Richmond, VA) was 
delivered subcutaneously for post-operative pain management.  Additionally, the 
anti-biotic Baytril® (Bayer Healthcare LLC Animal Health Division, Shawnee 
Mission, KS) was administered at a dosage of 2.5 mg/kg, delivered 
subcutaneously. The shaved area was aseptically prepared by scrubbing with the 
disinfectant anti-bacterial soap Hibiclens® (Molnlycke Heath Care US, LLC, 
Norcross, GA) followed by a wash with 70% ethanol, for approximately 3 to 5 
minutes.  This was performed using sterile gauze soaked in solution.  The area 
was then wiped with Betadine® (Purdue Products L.P., Stamford, CT). 
A median longitudinal skin incision was made over the patellar ligament of 
the knee.  The femoral condyle was exposed and a hole was created by the 
insertion of a 23 G spinal needle.  The 23 G spinal needle pin was inserted 
through the hole and down the femur until it contacted the proximal physis.  The 
spinal needle pin was then cut at the femoral condyle and was pushed under the 
condylar surface.  The wound was then closed using three to four absorbable 
sutures.  Once the pin was placed in the femur, the fractures were generated 
using a modification of the fracture machine described by Marturano et al. 
(2008).  The fracture machine is a device that has a blunt blade that is spring 
loaded and is driven by release of a weight from a set height.  The femur of the 
animals was positioned on a mount on two points under the blunt tipped blade, 
just touching the muscle over the lateral side of the mid-diaphyseal region of the 
20 
 
femur.  When the animals were correctly positioned, the blunt blade was dropped 
onto the bone, similar to the action of a guillotine, producing a three point 
bending that was carried onto the fixation pin.  This blunt trauma produced a 
single transverse closed fracture.  Initial assessment of the fracture was made by 
gentle palpation.  Confirmation of the fracture with no pin retraction was 
accomplished utilizing a dental X-ray unit that was purchased from Gendex, Inc. 
and was housed in the LASC procedure room.  X-rays were taken at a setting of 
60kV for 0.16 seconds using Kodak Ultra Speed DF-50 Size 4 film.  These films 
were manually developed on site in a hand developing box.  Animals that did not 
have a single transverse fracture were anesthetized again and placed on the 
fracture machine.  A second X-ray was taken to confirm fracture.   
 
Post-operative Treatment 
 Immediately after regaining consciousness from anesthesia the mice were 
ambulatory and were able to feed and drink.  The animals were monitored the 
next day and given injections of buprenorphine at 0.1 mg/kg as an analgesic.  
The mice were examined daily for signs of nerve damage, pin retraction, and any 
signs of failure to recover from injury.  The mice were subsequently removed 
from the phosphate deficient diet after the prescribed time of their enrollment 
group and returned to a normal diet for the duration of the experiment. 
 
Femora Harvesting  
21 
 
 Euthanasia was accomplished by carbon dioxide inhalation.  The animals 
were individually placed in an approved chamber and a carbon dioxide flow rate 
of 20% air displacement per minute was started.  Terminal cardiac bleeding after 
carbon dioxide asphyxiation was also performed and the blood was placed on ice 
and centrifuged.  The blood plasma was extracted and frozen for each animal for 
further studies evaluating the phosphate levels of the blood.  Finally, a cervical 
dislocation was performed.  X-rays were taken immediately following cervical 
dislocation utilizing a Faxitron MX-20 Specimen Radiography System for a time 
of 40 seconds at 30kV and a distance of approximately 13 cm.  Kodak BioMax 
XAR Scientific Imaging Film was used.   
 A small incision was made in the skin surrounding the right femur and the 
superficial layer of skin was removed from the muscle.  The femur was then 
harvested by means of a hemipelvectomy as well as disarticulation of the knee.  
The spinal needle pin was removed by forceps and the surrounding soft tissue 
was removed from the femur.  The femur was then cut proximal and distal to the 
fracture site and those pieces adjacent to the fracture site of the femur were 
frozen at -80° Celsius until the time of RNA extraction.  The contralateral femur of 
every animal on the phosphate restrictive diet was also harvested and frozen for 
future studies. 
 
RNA Extraction 
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 Femur samples were kept in liquid nitrogen when removed from the -80° 
Celsius freezer.  The samples were disrupted for molecular analysis using the 
Qiagen Tissue Lyser II®.  The bone was placed in a 2 ml tube filled with 0.75 ml 
Qiazol Lysis Reagent®.  The bone and lysis reagent were then flash-frozen in 
liquid nitrogen.  One 2mm stainless steel bead was placed in the tube and the 
tube was placed in the tissue lyser.  The bone was lysed for two minutes at 30 
Hz.  If samples were not completely lysed, the tube and its contents were placed 
in the liquid nitrogen again and the process was repeated.  Immediately after 
completion of that process, an additional 0.75 ml of Qiazol Lysis Reagent® was 
added and the tube was vortexed for approximately 10 seconds.  This was 
immediately followed by the addition of 200 µl of 1-Bromo-3-chloropropane.  The 
solution was then vortexed for an additional 10 seconds and placed on ice for 
two minutes.  The solution was then briefly vortexed again and centrifuged at 
14000 RPM and 4° C for 15 minutes.  The aqueous phase was transferred to a 
new 1.5 ml tube and an equal volume of isopropanol was added.  The tube was 
inverted several times until the liquid cleared and centrifuged again at 14000 
RPM and 4° C for 30 minutes.  The supernatant was removed and washed with 
500 µl of 70% ethanol and centrifuged at 14000 RPM and 4° C for 5 minutes – 
this process was repeated and the ethanol was removed.  The 1.5 ml tube was 
left on ice to dry the pellet containing the RNA.  The pellet was then dissolved in 
60 µl of RNase-free water and stored at -80° Celsius until cDNA generation.  
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cDNA Generation & qPCR Reaction 
The extracted RNA was thawed and a total of 2 µg was increased to a 
volume of 10.4 µl with RNase-free water in a 0.2 ml PCR tube. The reverse 
transcriptase reaction was carried out using the following reagents from the 
Taqman Reverse Transcription Kit®: MgCl2, dNTP Mix, 10X RT Buffer, and 
Random Hexamers.  The reagents were vortexed and the reverse transpcriptase 
enymes was added along with an RNase inhibitor.  The 10.4 µl of RNA was 
added to 19.6 µl of the reverse transcription polymerase chain reaction reagents 
for a total of 30 µl and lightly vortexed.  The tubes were placed in a thermal cycler 
to run the PCR cycle as follows: 25° C for 10 minutes, 37° C for 60 minutes, 95° 
C for 5 minutes, and held at 4° C.  The cDNA samples were then diluted 1:50 in 
RNase-free water and stored at -20° C until use. 
Quantitative real-time polymerase chain reaction (qPCR) was performed 
with Taqman MGB expression assays® (Applied Biosytems, Foster City, CA) 
using an ABI 7700 Sequence Detector® (Applied Biosystems).  Samples were 
run in triplicate and normalized to 18s rRNA in the same sample.  The fold 
change in expression was normalized to samples from fractured control B6 mice.  
 
Statistical Methods  
Statistical analysis was performed using Microsoft Excel 2010.  Group 
averages for qPCR data was computed along with standard deviation and 
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standard error.  Graphs were generated for mRNA expression of selected genes, 
including standard error bars. 
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RESULTS 
 
Radiographic Evaluation 
 Qualitative analysis of the radiographs collected post-mortem 
demonstrates that a phosphate restrictive diet delayed the fracture healing 
process in mice.  In all of the radiograph images, the distal end of the femur is 
located at the right side of the image and the proximal end of the femur is located 
at the left side of the image.  The arrows indicate the gap in the callus that is 
observable starting two weeks after fracture, based on the two-dimensional plain 
film x-rays. 
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Figure 5.  Day 3 Radiographs.  A: Control B: 5 Day Pi Restriction 
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Figure 6.  Day 5 Radiographs.  A: Control B: 5 Day Pi Restriction 
 
 
 
 
 
A      5 mm 
 
 
 
 
B     5 mm  
 
 
 
 
C     5 mm  
 
 
Figure 7.  Day 7 Radiographs.  A: Control B: 5 Day Pi Restriction C: 10 Day Pi Restriction 
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Figure 8.  Day 10 Radiographs.  A: Control B: 5 Day Pi Restriction C: 10 Day Pi Restriction 
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Figure 9.  Day 14 Radiographs.  A: Control B: 5 Day Pi Restriction C: 10 Day Pi Restriction D: 15 Day 
Pi Restriction 
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Figure 10.  Day 18 Radiographs.  A: Control B: 5 Day Pi Restriction C: 10 Day Pi Restriction D: 15 Day 
Pi Restriction E: 20 Day Pi Restriction 
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Figure 11.  Day 21 Radiographs.  A: Control B: 5 Day Pi Restriction C: 10 Day Pi Restriction D: 15 Day 
Pi Restriction E: 20 Day Pi Restriction 
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Figure 12.  Day 28 Radiographs.  A: Control B: 5 Day Pi Restriction C: 10 Day Pi Restriction D: 15 Day 
Pi Restriction E: 20 Day Pi Restriction 
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Figure 13.  Day 35 Radiographs.  A: Control B: 5 Day Pi Restriction C: 10 Day Pi Restriction D: 15 Day 
Pi Restriction E: 20 Day Pi Restriction 
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Table 5.  Number of Bridging Calluses Two Weeks after Injury.  The fraction represents the number of 
animals that had a bridging callus at the fracture site.  Because healing assessment was made using one-
dimensional plain film x-rays from a lateral view, bridging was considered achieved if one out of two 
cortices showed union. 
 
 14 
Day 
18 
Day 
21 
Day 
28 
Day 
35 
Day 
 
Control 
 
 
2/3 
 
2/3 
 
3/3 
 
3/3 
 
3/3 
5 Day Pi 
Restriction 
(5DR) 
 
1/3 
 
1/3 
 
1/3 
 
3/3 
 
3/3 
10 Day Pi 
Restriction 
(10DR) 
 
2/3 
 
2/3 
 
2/3 
 
3/3 
 
3/3 
15 Day Pi 
Restriction 
(15 DR) 
 
2/3 
 
1/3 
 
2/3 
 
3/3 
 
3/3 
20 Day Pi 
Restriction 
(20DR) 
  
1/3 
 
2/3 
 
2/3 
 
3/3 
 
The progression from initial injury to remodeled bone involves 
inflammation and endochondral formation, followed by primary and secondary 
bone formation (Gerstenfeld et al., 2003).  The endochondral callus formation 
follows the initial response of inflammation and usually begins one week post-
fracture.  The day 18 radiographs suggest that each group shows callus 
formation, although the size of the callus in the 15 and 20 day Pi restrictive diets 
is less than the control callus size, and bridging of the callus has not occurred in 
half of the animals.  This is consistent with what was observed during harvesting 
of the femurs at the 18 and 21 day time points.  After pin extraction and removal 
of the soft tissue surrounding the callus, the two ends of the bone held together 
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in the control, 5DR, and 10DR groups; however, in half of the animals, the ends 
of the bone in the 15DR and 20DR groups showed no union of the callus and the 
bone fell apart into the two pieces on each side of the fracture.  The process of 
primary bone formation occurs next.  Day 28 radiographs show the callus with 
the appearance of cartilage resorption in the control, 5DR, and 10DR groups; in 
contrast this process has not yet occurred in the 15DR and 20DR groups.  In all 
of the groups cartilage resorption is occurring at the 35 day time point. 
 
qPCR Analysis 
 The expression of marker genes that are associated with either the 
cartilage or bone formation were used to follow the progression of fracture 
healing. The genes that are associated with cartilage formation, or 
chondrogenesis, during the fracture healing process that were analyzed for this 
study were aggrecan (ACAN), collagen type II alpha 1 (COL2A1), collagen type 
X alpha 1 (COL10A1), transcription factor SOX5 (SOX5), and transcription factor 
SOX9 (SOX9).  The ACAN gene is responsible for the production of the 
proteoglycan aggrecan, which is a structural component of cartilage (Doege, 
Sasaki, Kimura, & Yamada, 1991).  COL2A1 and COL10A1 produce pro-alpha1 
type II collagen and alpha1 type X collagen respectively.  Type II collagen is 
found abundantly in cartilage, and type X collagen is expressed in hypertrophic 
chondrocytes during endochondral ossification (Apte, Mattei, & Olsen, 1991).  
The SOX9 and SOX5 genes produce transcription factors that control the 
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progression of chondrogenesis first from the earliest commitment stage (SOX9) 
through the cartilage progression (SOX5) which is present in mature non-
hypertrophic cartilage (Uusitalo et al., 2001).  Figures 14 and 15 show the 
relative fold change in expression of the two transcription factors that control 
chondrogenesis and three of the target genes of these factors that are related to 
the progression of chondrocyte differentiation.  In both figures, the control group 
is the dotted line. 
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Figure 14.  qPCR Analysis: Chondrogenesis (I).  Temporal gene expression profiles of three genes 
(COL2A1, ACAN, & COL10A1) associated with chondrogenesis. The solid red line represents the diet 
restrictive groups and the dotted black line is the control. 
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Figure 15.  qPCR Analysis: Chondrogenesis (II).  Temporal gene expression profiles of two genes 
(SOX9 & SOX5) associated with chondrogenesis.  The solid red line represents the diet restrictive groups 
and the dotted black line is the control. 
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The six genes that are associated with bone formation, or osteogenesis, 
during fracture healing that were analyzed for this study were runt-related 
transcription factor 2 (RUNX2), transcription factor osterix (OSX), dentin matrix 
acidic phosphoprotein 1 (DMP1), osteocalcin (OC), sclerostin (SOST), and 
DNA=binding protein inhibitor ID-1 (ID1).  The RUNX2 gene produces runt-
related transcription factor 2, a protein that is necessary for the differentiation of 
osteoblasts.  This transcription factor acts as a mediator for the time specific 
activation or inactivation of osteoblasts during differentiation that occurs during 
osteogenesis (Lian et al., 2004).  OSX is a gene that produces osterix, a 
transcription factor necessary for the progression and differentiation of 
mesenchymal stem cells to mature osteoblasts (Zhang et al., 2011).  The DMP1 
gene in osteoblasts produces dentin matrix acidic phosphoprotein and 
extracellular matrix protein necessary for the mineralization of bone (Narayanan 
et al., 2003).  OC expression in osteoblasts is typically used as a marker for the 
development of bone.  This gene produces osteocalcin which aids in bone 
mineralization as well as calcium homeostasis (Harada & Rodan, 2003; N.K. Lee 
et al., 2007).  Sclerostin is a glycoprotein produced by the SOST gene in 
osteocytes, which are mature osteoblasts trapped in bone matrix that are 
capable of resorbing bone through a process called osteocytic osteolysis.  
Studies on sclerostin have shown that this glycoprotein acts as an antagonist for 
BMP by binding to BMP receptors, leading to decreased BMP signaling and a 
subsequent decrease in mineralization of osteoblastic cells (Winkler et al., 2003).  
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Winkler et al. (2003) have also shown that transgenic mice that overexpress 
SOST exhibit decreased bone strength from low bone mass attributable to 
decreased osteoblast activity.  The ID1 gene produces DNA-binding protein 
inhibitor ID-1, which plays a role in cell growth and differentiation in bone growth 
with ID1 a direct BMP target gene (Korchynskyi & Dijke, 2002).  Figures 16 and 
17 show the relative fold change in expression of the genes related to 
osteogenesis.  In both figures, the control group is the dotted line. 
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Figure 16.  qPCR Analysis: Osteogenesis (I).  Temporal gene expression profiles of three genes 
(RUNX2, OSX, & ID1) associated with osteogenesis.  The solid red line represents the diet restrictive 
groups and the dotted black line is the control.  
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Figure 17.  qPCR Analysis: Osteogenesis (II).  Temporal gene expression profiles of two genes (OC, 
DMP1, & SOST) associated with osteogenesis.  The solid red line represents the diet restrictive groups and 
the dotted black line is the control. 
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DISCUSSION 
 
Effects on Gene Expression       
 All of the mice on a phosphate restrictive diet showed an overall increase 
in gene expression, with many of the genes exhibiting peak expression either 
before or after that observed in the control group.  For the chondrogenic genes, 
COL2A1, COL10A1, and SOX9 exhibited increased and earlier expression in all 
of the phosphate restrictive groups, and ACAN and SOX5 exhibited increased 
and later expression compared to the control group.  Control mice exhibit a peak 
expression of SOX5 three days after fracture.  Phosphate restricted mice exhibit 
peak SOX5 expression at the seven day time point.  The 10DR group exhibits 
another peak at 14 days, and the 15DR and 20DR groups show another peak at 
18 days and the 28 days respectively.  This delayed and biphasic expression of 
SOX5 may be reflective of the progressive delay of the transcriptional factors that 
controls cartilage maturation and to delay mineralization and development of the 
union. 
  Of the genes associated with osteogenesis, the control group exhibits a 
characteristic biphasic gene profile associated with primary and secondary bone 
formation in all of the genes except for OSX and SOST.  The restrictive 
phosphate groups exhibit what appears to be a leftward, or earlier, shift in gene 
expression.  Perhaps the most interesting result is the much earlier expression of 
SOST in the phosphate restrictive groups.  SOST expression begins to increase 
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at the 28 day time point in the control group, which is associated with the 
resorption of excess bone during the final remodeling phase of bone repair, and 
also the conversion of woven to lamellar bone.  In the phosphate restrictive 
groups, expression of SOST peaks at 10 days after fracture.  Perhaps the 
increase in the SOST gene product, sclerostin, is acting as an antagonist to 
several BMPs, which could potentially play a role in contributing to the delay in 
union.  
 
Future Directions         
 There are several elements of the study that still need to be carried out 
that will provide a more complete understanding of how low phosphate affects 
the healing process.  Some of the mice utilized for the study had fractures that 
were distal to the midpoint of the femur.  These mice, while walking, may have 
experienced more relative motion between the two bone ends.  Thus additional 
mice should be enrolled to remove any mice that did not have a true mid-
diaphyseal fracture.  Additionally, the serum of the blood that was extracted 
during the terminal bleeding of the mice should be evaluated.  Serum phosphate 
levels should be analyzed for each phosphate restrictive group in order to 
determine the degree of hypophosphatemia encounter in each diet restrictive 
group.  Since the only tissue level analysis of the delayed healing that was 
performed in this study were the x-ray assessments, a more definitive 
understanding will be achieved with histological examination.  Histologic 
44 
 
preparations at the callus site using selective staining for cartilage and 
mesenchymal tissues with safranin and fast green will allow us to definitively 
determine the nature of the tissues that are present in the calluses.  This will 
allow for histomorphometry of the areas of the callus that contain stromal cells, 
cartilage, and bone.   
 Another important aspect of the study will be to carry out three 
dimensional reconstruction using µCT of the callus to generate a structural and 
material measurement of the mineralized contents of the callus tissues.  Data 
generated from these scans provides quantitative measurements of total callus 
volume, cross-sectional area, mineral content and density, and mineralized 
tissue volume.  This will enable us to obtain a quantitative confirmation of the 
radiographic evidence suggesting that the phosphate restrictive diets delay the 
union of a fracture. 
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